Ulcerative Colitis Partnering 2007-2013

Keywords : Ulcerative colitis, colitis

The report will be delivered in PDF format within 3 working days of receipt of order. If print or CD-Rom version purchased, the report will be sent by courier using express service. The Ulcerative Colitis Partnering 2007-2013 report provides understanding and access to the ulcerative colitis partnering deals and agreements entered into by the worlds leading healthcare companies. •Trends in ulcerative colitis partneri...

More »

Please note: this report requires certain updates. We have all the information available but require 3 business days to complete the process and ensure it is as up-to-date as possible.

The report will be delivered in PDF format within 3 working days of receipt of order. If print or CD-Rom version purchased, the report will be sent by courier using express service.

The Ulcerative Colitis Partnering 2007-2013 report provides understanding and access to the ulcerative colitis partnering deals and agreements entered into by the worlds leading healthcare companies.


•Trends in ulcerative colitis partnering deals
•Top ulcerative colitis deals by value
•Deals listed by company A-Z, industry sector, stage of development, technology type



The Ulcerative Colitis Partnering 2007-2013 provides understanding and access to the ulcerative colitis partnering deals and agreements entered into by the worlds leading healthcare companies.



The report provides an analysis of ulcerative colitis partnering deals. The majority of deals are discovery or development stage whereby the licensee obtains a right or an option right to license the licensors ulcerative colitis technology. These deals tend to be multicomponent, starting with collaborative R&D, and commercialization of outcomes.



Understanding the flexibility of a prospective partner’s negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered – contract documents provide this insight where press releases do not.



This data driven report contains over 50 links to online copies of actual ulcerative colitis deals and contract documents as submitted to the Securities Exchange Commission by companies and their partners, where available. Contract documents provide the answers to numerous questions about a prospective partner’s flexibility on a wide range of important issues, many of which will have a significant impact on each party’s ability to derive value from the deal.



The initial chapters of this report provide an orientation of ulcerative colitis partnering trends.



Chapter 1 provides an introduction to the report, whilst chapter 2 provides an overview of the trends in ulcerative colitis partnering since 2007, including a summary of deals by industry sector, stage of development, deal type, and technology type. Numerous tables provide outline financial trends.



Chapter 3 provides an overview of the leading ulcerative colitis deals since 2007. Deals are listed by headline value, signed by bigpharma, most active bigpharma. Where the deal has an agreement contract published at the SEC a link provides online access to the contract.



Chapter 4 provides a comprehensive directory of ulcerative colitispartnering deals signed and announced since 2007. The chapter is organized by company A-Z, stage of development at signing, deal type (collaborative R&D, co-promotion, licensing etc), and technology type. Each deal title links via Weblink to an online version of the deal record, and where available the contract document, providing easy access to each contract document on demand.



In conclusion, this report provides everything a prospective dealmaker needs to know about partnering in the research, development and commercialization of ulcerative colitis technologies and products.



Report scope



Ulcerative Colitis Partnering 2007-2013 is intended to provide the reader with an in-depth understanding and access to ulcerative colitis trends and structure of deals entered into by leading companies worldwide.



This data driven report includes:


•Trends in ulcerative colitis dealmaking in the biopharma industry since 2007
•Access to summary headline, upfront, milestone and royalty data
•Access to over 50 ulcerative colitis contract documents
•The leading ulcerative colitis deals by value since 2007



In Ulcerative Colitis Partnering 2007-2013, the available deals are listed by:


•Headline value
•Upfront payment value
•Royalty rate value
•Company A-Z
•Industry sector
•Stage of development at signing
•Deal component type
•Technology type



Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.


Ulcerative Colitis Partnering 2007-2013 provides the reader with the following key benefits:


•In-depth understanding of ulcerative colitis reflux deal trends since 2007
•Access to summary headline, upfront, milestone and royalty data
•Comprehensive access to over 50 actual ulcerative colitis deals entered into by the world’s biopharma companies since 2007
•Insight into key deal terms included in contracts, where disclosed
•Understand the key deal terms companies have agreed in deals
•Undertake due diligence to assess suitability of your proposed deal terms for partner companies

Pathology Industry

Executive Summary



Chapter 1 – Introduction



Chapter 2 – Trends in ulcerative colitis partnering


•2.1. Introduction
•2.2. Ulcerative colitis partnering over the years
•2.3. Bigpharma ulcerative colitis dealmaking activity
•2.4. Ulcerative colitis partnering by deal type
•2.5. Ulcerative colitis partnering industry sector
•2.6. Ulcerative colitis partnering by stage of development
•2.7. Ulcerative colitis partnering by technology type
•2.8. Disclosed financial deal terms for ulcerative colitis partnering
•2.8.1 Ulcerative colitis headline values
•2.8.2 Ulcerative colitis upfront payments
•2.8.3 Ulcerative colitis milestone payments
•2.8.4 Ulcerative colitis royalty rates



Chapter 3 – Leading ulcerative colitis deals


•3.1. Introduction
•3.2. Top ulcerative colitis deals by value
•3.3. Top ulcerative colitis deals involving bigpharma



Chapter 4 – Dealmaking directory


•4.1. Introduction
•4.2. Company A-Z
•4.3. By deal type
•Asset purchase
•Bigpharma outlicensing
•Co-development
•Collaborative R&D
•Co-market
•Contract service
•Co-promotion
•CRADA
•Cross-licensing
•Development
•Distribution
•Equity purchase
•Evaluation
•Grant
•Joint venture
•Licensing
•Manufacturing
•Marketing
•Option
•Promotion
•Research
•Settlement
•Spin out
•Sub-license
•Supply
•Termination
•4.4. By industry sector
•Academic
•Bigpharma
•Biotech
•Drug delivery
•Medical device
•Diagnostic
•Generic pharma
•Government
•Non-profit
•Pharmaceutical
•Research tools
•Services
•Specialty pharma
•4.5. By stage of development
•Discovery
•Pre-clinical
•Phase I
•Phase II
•Phase III
•Registration
•Marketed
•4.6. By technology type
•Analysis
•Animal models
•Assays
•Bioinformatics
•Biological compounds
•Biomarkers
•Biomaterials
•Cell culture
•Cell therapy
•Clinical testing
•Diagnostic - companion
•Devices
•Diagnostics
•Discovery tools
•DNA probes
•Drug delivery
•Enabling technology
•Epigenetics
•Equipment
•Facilities
•Gene therapy
•Genomics
•Imaging
•Industrial chemicals
•In vitro models
•Monoclonal antibodies
•Nanotechnology
•Oligonucleotide
•Peptides
•Personalised medicine
•Processes
•Proteomics
•Radio/Chemo-therapy
•Recombinant DNA
•Research services
•Research supplies
•RNA therapeutics
•Screening
•Small molecules
•Stem cells
•Vaccines



Chapter 5 – Partnering resource center


•5.1. Online partnering
•5.2. Partnering events
•5.3. Further reading on dealmaking



Appendices


•Appendix 1 – Deal type definitions



About Wildwood Ventures


•Current Partnering
•Current Agreements
•Recent titles from CurrentPartnering
•Order Form – Reports



TABLE OF FIGURES


•Figure 1: ulcerative colitis partnering since 2007
•Figure 2: Bigpharma – top 50 – ulcerative colitis deals 2007 to 2011
•Figure 3: Bigpharma ulcerative colitis deal frequency – 2007 to 2011
•Figure 4: Ulcerative colitis partnering by deal type since 2007
•Figure 5: Ulcerative colitis partnering by industry sector since 2007
•Figure 6: Ulcerative colitis partnering by stage of development since 2007
•Figure 7: Ulcerative colitis partnering by technology type since 2007
•Figure 8: Ulcerative colitis deals with a headline value
•Figure 9: Ulcerative colitis deals with upfront payment values
•Figure 10: Ulcerative colitis deals with milestone payments
•Figure 11: Ulcerative colitis deals with royalty rates, %
•Figure 12: Top ulcerative colitis deals by value since 2007
•Figure 13: Top ulcerative colitis deals signed by bigpharma value since 2007
•Figure 14: Online partnering resources
•Figure 15: Forthcoming partnering events
•Figure 16: Deal type definitions